Vaccine maker Adimmune Corp (國光生技) yesterday said it plans to start in August phase I clinical trials of its COVID-19 vaccine candidate, which effectively inhibited the growth of the novel coronavirus in preliminary animal tests last month.
Adimmune told a news conference in Taipei that it had designed and produced four prototypes of antigens to fight the virus based on its recombinant protein technology, and last month tested one prototype in a biosafety level 3 (BSL-3) lab at National Taiwan University (NTU).
After injecting the antigen into a few mice and seeing them generate antibodies, Adimmune extracted their plasma and placed it in another cell as well as the novel coronavirus to test the outcome, the company said.
Photo: Chien Hui-ju, Taipei Times
“The tests showed that the antibodies could inhibit the growth of the novel coronavirus and remained fully capable with a dilution of 1:640,” NTU Department of Clinical Laboratory Sciences and Medical Biotechnology professor Chang Sui-yuan (張淑媛) said.
The inhibition rate remained above 80 percent with a dilution of 1:1280, attesting to the strong effect of the vaccine candidate, Adimmune chairman Steve Chan (詹啟賢) said, adding that a flu vaccine is regarded as effective if its inhibition rate is higher than 80 percent with a dilution of 1:320.
The virus tested was from an isolated strain with the highest toxicity among NTU’s more than 20 isolated virus strains, Chang said.
“The tests gave us encouraging results and we feel confident. However, given that the novel coronavirus mutates, we need to run tests on more virus strains to see if the candidate will work against most of them,” she said.
The lab spent about one month setting up protocols and conducting tests, she added.
Adimmune does not know how long the vaccine candidate can protect humans from the virus, but would find out the answers in the clinical trials, Chan said.
The firm on Tuesday began the second stage of animal tests to see if the vaccine candidate would endanger mice and plans to complete the tests in October, he said.
While most vaccine developers have to wait for animal tests to be completed and for the results to be confirmed before moving on to human tests, Adimmune plans to expedite the process by applying to conduct human trials in August, Chan said.
Like other foreign regulators worldwide, Taiwan’s Food and Drug Administration has launched emergency use authorizations programs to speed up the development of a treatment for COVID-19, he said.
Adimmune has been included in the agency’s program and would be granted priority when applying for reviews or clinical trials, the company said.
After completing the animal tests’ interim analysis to make sure its candidate is safe, Adimmune would apply to conduct phase I clinical trials in August, and commence phase II and phase III trials in the first quarter next year, Chan said.
“We have to take some risks here for if the animal tests turn up negative, the phase I trial will have to stop,” he said.
The company’s goal is to start mass production of the vaccines in December if it gains approval of an emergency use authorization by the Taiwanese regulators, before gaining marketing approval next year, he said.
Hon Hai Precision Industry Co (鴻海精密) yesterday said that its research institute has launched its first advanced artificial intelligence (AI) large language model (LLM) using traditional Chinese, with technology assistance from Nvidia Corp. Hon Hai, also known as Foxconn Technology Group (富士康科技集團), said the LLM, FoxBrain, is expected to improve its data analysis capabilities for smart manufacturing, and electric vehicle and smart city development. An LLM is a type of AI trained on vast amounts of text data and uses deep learning techniques, particularly neural networks, to process and generate language. They are essential for building and improving AI-powered servers. Nvidia provided assistance
GREAT SUCCESS: Republican Senator Todd Young expressed surprise at Trump’s comments and said he expects the administration to keep the program running US lawmakers who helped secure billions of dollars in subsidies for domestic semiconductor manufacturing rejected US President Donald Trump’s call to revoke the 2022 CHIPS and Science Act, signaling that any repeal effort in the US Congress would fall short. US Senate Minority Leader Chuck Schumer, who negotiated the law, on Wednesday said that Trump’s demand would fail, while a top Republican proponent, US Senator Todd Young, expressed surprise at the president’s comments and said he expects the administration to keep the program running. The CHIPS Act is “essential for America leading the world in tech, leading the world in AI [artificial
DOMESTIC SUPPLY: The probe comes as Donald Trump has called for the repeal of the US$52.7 billion CHIPS and Science Act, which the US Congress passed in 2022 The Office of the US Trade Representative is to hold a hearing tomorrow into older Chinese-made “legacy” semiconductors that could heap more US tariffs on chips from China that power everyday goods from cars to washing machines to telecoms equipment. The probe, which began during former US president Joe Biden’s tenure in December last year, aims to protect US and other semiconductor producers from China’s massive state-driven buildup of domestic chip supply. A 50 percent US tariff on Chinese semiconductors began on Jan. 1. Legacy chips use older manufacturing processes introduced more than a decade ago and are often far simpler than
Gasoline and diesel prices this week are to decrease NT$0.5 and NT$1 per liter respectively as international crude prices continued to fall last week, CPC Corp, Taiwan (CPC, 台灣中油) and Formosa Petrochemical Corp (台塑石化) said yesterday. Effective today, gasoline prices at CPC and Formosa stations are to decrease to NT$29.2, NT$30.7 and NT$32.7 per liter for 92, 95 and 98-octane unleaded gasoline respectively, while premium diesel is to cost NT$27.9 per liter at CPC stations and NT$27.7 at Formosa pumps, the companies said in separate statements. Global crude oil prices dropped last week after the eight OPEC+ members said they would
RSS